Market Overview

Morgan Stanley: Veeva Systems' Share Price Fails To Reflect Growth, Margin Potential

Morgan Stanley: Veeva Systems' Share Price Fails To Reflect Growth, Margin Potential
Related VEEV
Veeva Systems Q4 Earnings Preview
Vetr Crowd Downgrades Veeva Systems

Veeva Systems Inc (NYSE: VEEV), a cloud-computing company focused on the pharma and life sciences industry, is an underpriced asset within the broader SaaS universe, according to Morgan Stanley. 

The Analyst

Morgan Stanley analyst Stan Zlotsky upgraded Veeva Systems from Equal-weight to Overweight and increased the price target from $69 to $72.

The Thesis

Veeva Systems has durable growth — fueled by an expanding $17-billion total addressable market — and margin potential that is not being reflected in current trading levels, Zlotsky said in a Tuesday note. A conservative setup into 2019 offers scope for estimates and shares to move up, he said. 

The company's best-in-class economics are likely to drive longer-term operating margin to 43 percent, representing the highest margin potential in Morgan Stanley's coverage universe, Zlotsky said.

"Veeva's above average sales efficiency and a disciplined go-to-market has enabled the company to simultaneously deliver strong revenue growth and greater than 30-percent operating margins today, well above the 18-percent average among more mature SaaS peers," the analyst said. 

Morgan Stanley estimates 16-percent revenue growth on a CAGR basis to $1.7 billion and a 36-percent operating margin by calendar year 2023, resulting in free cash flow of $593 million. 

With the 12-percent pullback in Veeva Systems shares since June 2017 compared to a 14-percent gain for the SaaS peer group, Morgan Stanley sees an attractive entry point to rebuild positions in the shares.

The Price Action

Veeva Systems shares are up over 41 percent year-to-date.

Shares were up 0.60 percent at $60.68 after the open Tuesday.

Related Links:

Mizuho: After Industry Consolidation, Cloudera Emerges As A Buy

6 Reasons To Hold On To Salesforce Stock

Latest Ratings for VEEV

Mar 2018JP MorganDowngradesOverweightNeutral
Mar 2018KeyBancMaintainsOverweightOverweight
Mar 2018Morgan StanleyMaintainsOverweightOverweight

View More Analyst Ratings for VEEV
View the Latest Analyst Ratings

Posted-In: cloud computing life sciences Morgan Stanley pharmaAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (VEEV)

View Comments and Join the Discussion!